Search

Your search keyword '"M. A. Trubnikova"' showing total 8 results
Start Over Author "M. A. Trubnikova" Search Limiters Full Text
8 results on '"M. A. Trubnikova"'

1. Clinical features of post-COVID period. Results of an International Register 'Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)' (12-month follow-up)

Author

G. P. Arutyunov, E. I Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigorieva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateishchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanav, S. A. Sayganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Sh'ukarev, A. K. Abdrakhmanova, S. A. Avetisian, H. G. Avoyan, K. K. Azarian, G. T. Aimakhanova, D. A. Ayipova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, T. I. Batluk, A. S. Batchayeva, R. A. Bashkinov, A. M. Bitieva, I. U. Bikhteyev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Gаlova, V. V Genkel, D. B. Giller, E. I. Gorshenina, E. V. Grigorieva, E. U. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duyshobayev, D. S. Evdokimov, K. E. Egorova, A. E. Zheldybayeva, N. V. Zarechnova, Yu. D. Zimina, S. U. Ivanova, E. U. Ivanchenko, M. V. Ilina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Кaskaeva, K. F. Kasymova, Zh. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Koliadich, O. V. Kondriakova, M. P. Konoval, D. U. Konstantinov, E. A. Konstantinova, V. A. Kordukova, E. V. Koroleva, A. U. Kraposhina, T. V. Kryukova, A. S. Kuznetsova, T. U. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. U. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeyeva, K. V. Mazalov, V. I. Maiseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelian, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. U. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A. Pavlova, E. V. Pahomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofeva, J. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, I. V. Samus, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortcova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagayeva, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostianetckaia, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. U. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. U. Shishkov, S. U. Sherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
covid-19, post-covid period, readmissions, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To investigate on post-COVID period in patients of the Eurasian region.Material and methods. A total of 9364 consecutively hospitalized patients were included in ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to ACTIV register, 63% of patients after COVID-19 had new adverse symptoms or exacerbations of the existing symptoms lasting for up to 1 year. After hospital discharge, 79,8% of patients sought unscheduled medical attention in the first 3 months, 79,1% at 4-6 months, and 64,8% at 7-12 months. Readmission rate was 11,8% in the first 3 months, 10,9% at 4-6 months, and 10,1% at 7-12 months. The most common reasons for unscheduled treatment in the first 3 months were uncontrolled hypertension, decompensated type 2 diabetes, destabilization of coronary artery disease, gastrointestinal disease, AF episodes, exacerbation of asthma and chronic obstructive pulmonary disease, decompensated heart failure (HF). The 12-month mortality of COVID-19 survivors after the discharge was 3,08%. Multivariate analysis showed that independent risk factors for fatal outcome were age (direct correlation), the levels of hemoglobin (inverse correlation), oxygen saturation (inverse correlation), and aspartate aminotransferase (direct correlation), as well as class III-IV HF, prior stroke, cancer, inhospital acute kidney injury. Based on these identified risk factors, a nomogram was constructed to determine the 3-month mortality risk after discharge.Conclusion. Analysis of ACTIV register showed that end of the acute phase of COVID-19 does not imply a complete recovery.

Published
2023
Full Text
View/download PDF

2. Lipid profile in hospitalized patients with COVID-19 depending on the outcome of its acute phase: data from the international registry 'Dynamics analysis of comorbidities in SARS-CoV-2 infection survivors'

Author

G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, G. G. Airapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigorieva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateyshchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanov, S. A. Saiganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Schukarev, A. K. Abdrakhmanova, S. A. Avetisyan, O. G. Avoyan, K. K. Azaryan, G. T. Aimakhanova, D. A. Aiypova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, T. I. Batluk, A. S. Batchaeva, R. A. Bashkinov, A. M. Bitieva, I. U. Bikhteev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Galova, V. V. Genkel, D. B. Giller, E. I. Gorshenina, E. V. Grigoryeva, E. Yu. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duishobaev, D. S. Evdokimov, K. E. Egorova, A. N. Ermilova, A. E. Zheldybaeva, N. V. Zarechnova, Yu. D. Zimina, S. Yu. Ivanova, E. Yu. Ivanchenko, M. V. Ilyina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Kaskaeva, K. F. Kasymova, J. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, A. V. Klimova, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Kolyadich, O. V. Kondryakova, M. P. Konoval, D. Yu. Konstantinov, E. A. Konstantinova, V. A. Kordyukova, E. V. Koroleva, A. Yu. Kraposhina, T. V. Kryukova, A. P. Kuznetsova, T. Yu. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. Yu. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeeva, K. V. Mazalov, V. I. Mayseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelyan, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. Yu. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A. Pavlova, E. V. Pakhomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofieva, Yu. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortsova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagaeva, Yu. V. Titoikina, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostyanetskaya, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. Yu. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. Yu Shishkov, S. Yu. Shcherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
covid-19, low density lipoproteins, cholesterol, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To study the lipid profile in hospitalized patients with coronavirus disease 2019 (COVID-19) depending on the outcome of its acute phase according to the AKTIV international registry.Material and methods. The AKTIV registry included men and women over 18 years of age with a diagnosis of COVID-19, who were treated in a hospital. A total of 9364 patients were included in the registry, of which 623 patients were analyzed for levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides on days 1-2 of hospitalization. The level of high-density lipoprotein cholesterol (HDL-C) was calculated using the Friedewald equation.Results. We found that a decrease in LDL-C level was significantly associated with an unfavorable prognosis for hospitalized patients with COVID-19. This pattern persisted in both univariate and multivariate analyses. LDL-C levels in the final multivariate model had a significant relationship with the prognosis (an increase in the death risk by 1,7 times with a decrease per 1 mmol/l). In addition, we found that the survival of patients with an indicator level of

Published
2022
Full Text
View/download PDF

3. Multifocal atherosclerosis: focus on the prevention of ischemic events

Author

A. G. Arutyunov, T. I. Batluk, R. A. Bashkinov, and M. A. Trubnikova

Subjects
multifocal atherosclerosis, peripheral arterial disease, coronary artery disease, anticoagulant therapy, antiplatelet therapy, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

In patients with atherosclerotic lesions of two or more systems or multifocal atherosclerosis (MFA), the risks of ischemic events are extremely high. MFA leads not only to cardiovascular outcomes, but also to a decrease in the patient’s quality of life, life expectancy, and in most cases to disability. The prevalence of this pathology and the importance of preventing adverse outcomes are often underestimated. This literature review examines the problem of MFA in the context of key studies on the prevalence, course of multivessel disease and the reduction of the risk of cardiovascular events in this group of patients, with an emphasis on antiplatelet and anticoagulant therapy.

Published
2022
Full Text
View/download PDF

4. Clinical features of post-COVID-19 period. Results of the international register 'Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)'. Data from 6-month follow-up

Author

G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigorieva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanau, S. A. Sayganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Shchukarev, A. K. Abdrahmanova, S. A. Avetisian, H. G. Avoyan, K. K. Azarian, G. T. Aimakhanova, D. A. Ayipova, A. Ch. Akunov, M. K. Alieva, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barisheva, T. I. Batluk, A. S. Batchayeva, R. A. Bashkinov, A. M. Bitieva, I. U. Bikhteyev, N. A. Borodulina, M. V. Bragin, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Gаlova, V. V. Genkel, E. I. Gorshenina, E. V. Grigorieva, E. Yu. Gubareva, G. M. Dabylova, I. A. Demchenko, O. Yu. Dolgikh, M. Y. Duyshobayev, D. S. Evdokimov, K. E. Egorova, A. N. Ermilova, A. E. Zheldybayeva, N. V. Zarechnova, Yu. D. Zimina, S. Yu. Ivanova, E. Yu. Ivanchenko, M. V. Ilina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. K. Karsiev, D. S. Кaskaeva, K. F. Kasymova, Zh. B. Kerimbekova, A. Sh. Kerimova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, A. V. Klimova, O. V. Kovalishena, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Kolyadich, O. V. Kondriakova, M. P. Konoval, D. Yu. Konstantinov, E. A. Konstantinova, V. A. Kordukova, E. V. Koroleva, A. Yu. Kraposhina, T. V. Kriukova, A. S. Kuznetsova, T. Yu. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kouranova, L. V. Kurenkova, N. Yu. Kurchugina, N. A. Kushubakova, V. I. Levankova, N. A. Lyubavina, N. A. Magdeyeva, K. V. Mazalov, V. I. Majseenko, A. S. Makarova, A. M. Maripov, A. A. Marusina, E. S. Melnikov, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelian, A. O. Myshak, E. S. Nekaeva, N. M. Nikitina, B. B. Ogurlieva, A. A. Odegova, Yu. M. Omarova, N. A. Omurzakova, Sh. O. Ospanova, E. V. Pahomova, L. D. Petrov, S. S. Plastinina, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, N. A. Prokofeva, I. A. Pudova, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, S. Serikbolkyzy, A. A. Simonov, V. V. Skachkova, D. V. Soloveva, I. A. Soloveva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagayeva, Yu. V. Titojkina, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostianetckaia, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. Yu. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, O. A. Shevchenko, T. V. Sheshina, E. A. Shishkina, K. Yu. Shishkov, S. Yu. Sherbakov, and E. A. Yausheva

Subjects
covid-19, aktiv register, cardiovascular diseases, diabetes, postcovid-19 period, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To study the clinical course specifics of coronavirus disease 2019 (COVID-19) and comorbid conditions in COVID-19 survivors 3, 6, 12 months after recovery in the Eurasian region according to the AKTIV register. Material and methods.The AKTIV register was created at the initiative of the Eurasian Association of Therapists. The AKTIV register is divided into 2 parts: AKTIV 1 and AKTIV 2. The AKTIV 1 register currently includes 6300 patients, while in AKTIV 2 — 2770. Patients diagnosed with COVID-19 receiving in- and outpatient treatment have been anonymously included on the registry. The following 7 countries participated in the register: Russian Federation, Republic of Armenia, Republic of Belarus, Republic of Kazakhstan, Kyrgyz Republic, Republic of Moldova, Republic of Uzbekistan. This closed multicenter register with two nonoverlapping branches (in- and outpatient branch) provides 6 visits: 3 in-person visits during the acute period and 3 telephone calls after 3, 6, 12 months. Subject recruitment lasted from June 29, 2020 to October 29, 2020. Register will end on October 29, 2022. A total of 9 fragmentary analyzes of the registry data are planned. This fragment of the study presents the results of the post-hospitalization period in COVID-19 survivors after 3 and 6 months. Results. According to the AKTIV register, patients after COVID-19 are characterized by long-term persistent symptoms and frequent seeking for unscheduled medical care, including rehospitalizations. The most common causes of unplanned medical care are uncontrolled hypertension (HTN) and chronic coronary artery disease (CAD) and/or decompensated type 2 diabetes (T2D). During 3- and 6-month follow-up after hospitalization, 5,6% and 6,4% of patients were diagnosed with other diseases, which were more often presented by HTN, T2D, and CAD. The mortality rate of patients in the post-hospitalization period was 1,9% in the first 3 months and 0,2% for 4-6 months. The highest mortality rate was observed in the first 3 months in the group of patients with class II-IV heart failure, as well as in patients with cardiovascular diseases and cancer. In the pattern of death causes in the post-hospitalization period, following cardiovascular causes prevailed (31,8%): acute coronary syndrome, stroke, acute heart failure. Conclusion. According to the AKTIV register, the health status of patients after COVID-19 in a serious challenge for healthcare system, which requires planning adequate health system capacity to provide care to patients with COVID-19 in both acute and post-hospitalization period.

Published
2021
Full Text
View/download PDF

5. Impact of Kidney Damage on the Course and Prognosis of COVID-19 Infection According to the International Registry «Analysis of Chronic Non-Infectious Diseases Dynamics After Covid-19 Infection in Adult Patients»

Author

M. M. Batiushin, M. A. Trubnikova, E. I. Tarlovskaya, G. P. Arutyunov, T. I. Batluk, R. A. Bashkinov, E. S. Melnikov, and A. G. Arutyunov

Subjects
General Medicine
Abstract

Objective. To study the course of the new coronavirus infection in patients with chronic kidney disease (CKD), to identify cases of acute kidney injury (AKI) in the setting of COVID-19 infection, and to access the impact of renal function on prognosis in these categories of patients during the acute phase and after hospitalization, at 3, 6, and 12 months after recovery. Materials and methods. The ACTIV and ACTIV 2 registries included men and women older than 18 years with a diagnosis of COVID-19 based on a positive PCR test for COVID-19 and a characteristic chest X-ray or computed tomography chest scan. Results. A total of 9364 patients (4404 men, average age59 [48-69]) were included in the analysis. 716 (7.67 %) patients had CKD. 8496 (90,7 %) patients had their glomerular filtration rate (GFR) measured during hospitalization, and the values were distributed as follows: ≥90 ml/min/1.73m2 – in 4289 (50,5 %) patients, 89-60 ml/min/1.73m2 — in 3150 (37,1 %) patients, 59-45 ml/min/1.73m2 — in 613 (7,22 %), 44-30 ml/min/1.73m2 — in 253 (2,98 %), 29-15 ml/min/1.73m2 — in 110 (1,29 %), 2 — in 81 (0,95 %) patients. 11.6 % of the subjects (n=1068) developed AKI during hospitalization. This complication was reported more often than cytokine storm (in 7.46 % in 687 patients, рConclusion. The prevalence of CKD in COVID-19 patients is similar to that in the general population. AKI developed in 11.6 % of cases with COVID-19 infection and was observed more frequently in patients with overweight and hyperglycemia. CKD and AKI increased the risk of hospital mortality in patients with COVID-19. In the group of patients with CKD, mortality increased in the post-COVID period, 3, 6 and 12 months after. The high mortality rate of patients who had AKI during the coronavirus infection was observed only in the first 3 months of follow-up in the post-COVID period.

Published
2023

6. The impact of carbohydrate metabolism disorders on the early and long-term clinical outcomes of patients with COVID-19 according to the AKTIV and AKTIV 2 registries

Author

V. V. Salukhov, G. P. Arutyunov, E. I. Tarlovskaya, T. I. Batluk, R. A. Bashkinov, I. V. Samus, E. S. Melnikov, M. A. Trubnikova, and A. G. Arutyunov

Subjects
Endocrinology, Diabetes and Metabolism
Abstract

BACKGROUND: Numerous studies indicate a high incidence of various disorders of carbohydrate metabolism against the new coronavirus infection. These disorders aggravate the course of infection and increase mortality. Thereby, analysis of risk factors for unfavorable outcomes and assessment of the long-term consequences of COVID-19 in patients with impaired carbohydrate metabolism is of great importance.AIM: To investigate the association between carbohydrate metabolism disorders in COVID-19 patients and mortality, course of infection, long-term consequences, as well as to identify risk factors for an unfavorable disease course.MATERIALS AND METHODS: A retrospective analysis of data from the combined multicenter non-interventional real-world AKTIV and AKTIV 2 registries was performed. The sample included 9290 patients who had COVID-19 with varying severity from June 29, 2020, to November 29, 2020 (AKTIV) and from October 01, 2020, to March 30, 2021 (AKTIV 2). The patients were divided into 3 groups: Group 1 — patients with intact carbohydrate metabolism, n=6606; Group 2 — patients with newly diagnosed hyperglycemia (NDH), n=1073; Group 3 — patients with a history of type 2 diabetes mellitus (DM2), n=1611. The groups were assessed for clinical and laboratory parameters, comorbidities, mortality, carbohydrate metabolic status, and well-being during the infection and at 12 months.RESULTS: The prevalence of carbohydrate metabolism disorders (CMD) was 28,9%, with DM2 patients accounting for 17,3% and patients with newly diagnosed hyperglycemia (NDH) for 11,6%. The mortality rate of patients with hyperglycemia of any origin was 10.6%, which was significantly higher compared to patients without hyperglycemia (3,9%). The probability of lethal outcome increased 2,48-fold in the group of patients with DM2 and 2,04-fold in the group of patients with NDH. At the same time, the probability of a lethal outcome decreased 2,94-fold in patients without CMD. At 12 months, patients with CMD showed a significantly higher frequency and longer persistence of complaints. This trend was more pronounced in patients with DM2 than in those with NDH. Only 1,7% of patients from the NDH group had type 2 diabetes and were receiving oral hypoglycemic medications one year after the infection. A prognostic model was developed to determine the risk of lethal outcome. The model included such known predictors as concomitant ischemic heart disease, history of myocardial infarction or stroke, blood glucose level, and age.CONCLUSION: Carbohydrate metabolism disorders aggravate the course of COVID-19 and increase mortality. One year after infection, patients with DM2 and NDH were more likely to have symptoms typical for post-COVID syndrome, and NDH resolved in most cases after the infection.

Published
2023

7. The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries

Author

A. G. Arutyunov, E. I. Tarlovskaya, G. R. Galstyan, T. I. Batluk, R. A. Bashkinov, G. P. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigoryeva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateishchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanov, S. A. Saiganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Schukarev, A. K. Abdrakhmanova, S. A. Avetisyan, H. G. Avoyan, K. K. Azaryan, G. T. Aimakhanova, D. A. Ayypova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, A. S. Batchaeva, A. M. Bitieva, I. U. Bikhteev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Galova, V. V. Genkel, D. B. Giller, E. I. Gorshenina, E. V. Grigoryeva, E. Yu. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duishobaev, D. S. Evdokimov, K. E. Egorova, A. N. Ermilova, A. E. Zheldybaeva, N. V. Zarechnova, Yu. D. Zimina, S. Yu. Ivanova, E. Yu. Ivanchenko, M. V. Ilina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Kaskaeva, K. F. Kasymova, Zh. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, A. V. Klimova, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Kolyadich, O. V. Kondryakova, M. P. Konoval, D. Yu. Konstantinov, E. A. Konstantinova, V. A. Kordyukova, E. V. Koroleva, A. Yu. Kraposhina, T. V. Kryukova, A. S. Kuznetsova, T. Yu. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. Yu. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeeva, K. V. Mazalov, V. I. Mayseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelyan, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. Yu. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A. Pavlova, E. V. Pakhomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofieva, Yu. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, I. V. Samus, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortsova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagaeva, Yu. V. Titoykina, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostyanetskaya, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. Yu. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. Yu. Shishkov, S. Yu. Shcherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
Endocrinology, Diabetes and Metabolism
Abstract

BACKGROUND. There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).AIM. To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.MATERIALS AND METHODS. AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected the data of hospitalized patients and included 3 visits. All subjects were divided into 3 groups: not overweight (n=2139), overweight (n=2931) and obese (n=2666).RESULTS. A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (pCONCLUSION. Overweight and/or obesity is a significant risk factor for severe course of the new coronavirus infection and the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.

Published
2023

8. Newly diagnosed diseases and the frequency of their occurrence in patients after a new coronavirus infection. Results of an International Register 'Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)' (12-month follow-up)

Author

G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, D. S. Polyakov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigoryeva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateishchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanov, S. A. Saiganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Schukarev, A. K. Abdrakhmanova, S. A. Avetisyan, H. G. Avoyan, K. K. Azaryan, G. T. Aimakhanova, D. A. Ayypova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, O. Yu. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, T. I. Batluk, A. S. Batchaeva, R. A. Bashkinov, A. M. Bitieva, I. U. Bikhteev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. .A. Vinnikova, V. V. Vustina, E. A. Elena A. Galova, V. V. Genkel, D. B. Giller, E. D. Gordeychuk, E. I. Gorshenina, E. V. Grigoryeva, E. Yu. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duishobaev, D. S. Evdokimov, K. E. Egorova48, A. E. Zheldybaeva, N. V. Zarechnova, Yu. D. Zimina, S. Yu. Ivanova, E. Yu. Ivanchenko, M. V. Ilina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Yuliya S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Kaskaeva, K. F. Kasymova, Zh. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Kolyadich, O. V. Kondryakova, M. P. Konoval, D. Yu. Konstantinov, E. A. Konstantinova, V. A. Kordyukova, E. V. Koroleva, A. Yu. Kraposhina, T. V. Kryukova, A. S. Kuznetsova, T. Yu. Kuzmina, K. V. Kuzmichev, C. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. Yu. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeeva, K. V. Mazalov, V. I. Mayseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelyan, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. Yu. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Yuliya V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A/ Pavlova, E. V. Pakhomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofieva, Yu. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortsova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagaeva, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostyanetskaya, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. Yu. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. Yu. Shishkov, S. Yu Shcherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
Cardiology and Cardiovascular Medicine
Abstract

Aim. To analyze newly diagnosed diseases and features of the post-COVID course in patients after a coronavirus disease 2019 (COVID-19) within 12-month follow-up.Material and methods. A total of 9364 consecutively hospitalized patients were included in the ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to the ACTIV registry, 18,1% of patients after COVID-19 had newly diagnosed diseases (NDDs) over the next 12 months. Hypertension (HTN), type 2 diabetes and coronary artery disease (CAD) prevailed in the NDD structure. Comparison of the age-standardized incidence of NDDs (HTN, CAD, diabetes) in the post-COVID period in the ACTIV registry with NDD incidence in 2019 according to Rosstat and the expected incidence of NDDs according to the EPOHA study revealed that HTN, diabetes, CAD in patients after COVID-19 were registered more often as follows: HTN by 7,0 and 4,4 times, diabetes by 7,3 and 8,8 times, CAD by 2,3 and 2,9 times, respectively. NDDs most often developed in patients aged 47 to 70 years. Comparison of the actual and expected number of cases of newly diagnosed HTN, CAD and diabetes depending on age showed that the actual number of cases in the population of patients in the ACTIV register is significantly higher than expected for patients aged 45-69 years and for patients with hypertension or diabetes and aged Conclusion. Available evidence suggests that a strategy for managing COVID-19 survivors should include mandatory screening for early detection of cardiovascular disease and diabetes, which will be key to reducing the risk of further COVID-19 consequences.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results